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Abstract: Skeletal-related events (SREs) including pain, fractures, and hypercalcemia are 
a major source of morbidity for cancer patients with bone metastases. The receptor activator 
of NF-κB ligand (RANKL) is a key mediator of osteoclast formation and activity in normal 
bone physiology as well as cancer-induced bone resorption. The first commercially available 
drug that specifically targets and inhibits the RANKL pathway is denosumab, a fully human 
monoclonal antibody that binds and neutralizes RANKL, thereby inhibiting osteoclast function. 
In this review, we summarize the major studies leading to the US Food and Drug Administration-
approval of denosumab for the prevention of SREs in patients with bone metastases from solid 
tumors. Further, we discuss the role of denosumab in the prevention and treatment of SREs 
and bone loss in cancer patients. As a monoclonal antibody, denosumab has several advantages 
over bisphosphonates, including improved efficacy, better tolerability, and the convenience of 
administration by subcutaneous injection. In addition, as denosumab has no known renal toxicity, 
it may be the preferred choice over bisphosphonates in patients with baseline renal insufficiency 
or receiving nephrotoxic therapies. However, other toxicities, including osteonecrosis of the 
jaw and hypocalcemia, appear to be class effects of agents that potently inhibit osteoclast 
activity and are associated with both denosumab and bisphosphonate use. The data presented 
highlight the differences associated with intravenous bisphosphonate and denosumab use as 
well as confirm the essential role bone-modifying agents play in maintaining the quality of life 
for patients with bone metastases.
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Introduction
Bone is the most common site of metastatic disease in patients with solid tumors. 
Approximately 30%–40% of patients with lung cancer and 20%–25% of patients 
with advanced renal cell carcinoma are found to have bone metastasis on autopsy.1 
In patients with metastatic breast and prostate cancer, 65%–80% will develop bone 
metastasis, and bone is the most common site of first recurrence in breast cancer 
patients.1,2 In addition, pain from bone metastasis is the most frequent form of pain 
reported in patients with cancer.3 Patients with metastatic disease of the bone are at 
risk for skeletal-related events, which are defined as: radiation therapy to alleviate pain 
or prevent fracture, surgery to prevent or treat fracture, pathologic fracture (excluding 
major trauma), spinal cord compression, and other complications related to skeletal 
involvement, including hypercalcemia of malignancy. Skeletal-related events are thus 
a major source of morbidity for cancer patients.
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Cancer patients often experience multiple skeletal-
related events over the course of their disease. Patients 
with metastatic breast cancer experience an average of four 
skeletal-related events, lung cancer patients approximately 
2.7 skeletal-related events, and prostate cancer patients an 
average 1.5 skeletal-related events over the course of their 
disease if untreated.4–6 Skeletal-related events also add 
considerable costs to the management of patients with bone 
metastases and can be a major cause of hospitalization. 
Fractures are the most commonly reported skeletal-related 
events and occur in up to 60% of untreated breast cancer 
patients with bone metastasis.7 Bone metastases cause pain, 
limited mobility, fears of future fracture, and loss of function, 
significantly decreasing quality of life. Thus, the prevention 
of skeletal-related events in patients with metastatic solid 
tumors is a vital component of their oncologic care.
Since the 1990s, bisphosphonates have been the mainstay 
of treatment to prevent skeletal-related events in patients 
with cancer metastases to bone. Bisphosphonates are rapidly 
incorporated into bone and are released during osteoclast-
mediated bone resorption, where they impair the ability of 
osteoclasts to adhere to the bony surface and inhibit continued 
bone resorption. Bisphosphonates also decrease osteoclast 
progenitor development and recruitment, and induce 
osteoclast apoptosis. The most commonly used intravenous 
bisphosphonates are zoledronic acid (Zometa®, Novartis 
Pharmaceuticals East Hanover, NJ) and pamidronate 
(Aredia®, Novartis Pharmaceuticals East Hanover, NJ).
Zoledronic acid is the most potent bisphosphonate 
currently available, 500–1000 times more potent than 
pamidronate, and is the first drug in this class approved for use 
in all solid tumor patients with bone metastases as well as in 
multiple myeloma. Its use has been studied most extensively 
in breast cancer, prostate cancer, multiple myeloma, and 
lung cancer.4,5,8–11 Despite optimal bisphosphonate therapy, 
30%–50% of cancer patients with bone metastases still 
develop skeletal-related events while on bisphosphonate 
therapy.5,8 In addition, there are concerning treatment-related 
side effects associated with bisphosphonates, including 
gastrointestinal irritation, nephrotoxicity, osteonecrosis of the 
jaw, and hypocalcemia. Intravenous infusion of zoledronic 
acid can be associated with an acute-phase reaction, including 
bone pain, fever, and chills in up to 30% of patients following 
their first infusion. In addition, intravenous bisphosphonates, 
and in particular zoledronic acid carry the risk of renal 
toxicity that is dose-dependent and infusion time-dependent. 
Zoledronic acid is currently not recommended for use in 
patients with a creatinine clearance lower than 30 mL/minute 
and must be dose-reduced if creatinine clearance is less 
than 60 mL/minute.12 Consequently, monthly monitoring of 
renal function is required prior to each dose of intravenous 
bisphosphonate. The use of bisphosphonates in patients with 
solid tumors and renal dysfunction is thus limited and the 
concomitant use of zoledronic acid with other nephrotoxic 
drugs or chemotherapeutic agents can be problematic.
Receptor activator of NF-κB ligand (RANKL)-mediated 
osteoclast activity is a key regulator of bone metabolism. 
RANKL is produced by osteoblasts, bone marrow 
stromal cells, and other cells under the control of various 
proresorptive growth factors, hormones, and cytokines. 
Osteoblasts and stromal cells produce osteoprotegerin, a 
decoy receptor, which binds to and inactivates RANKL. 
In the absence of osteoprotegerin, RANKL activates 
the RANK receptor, which is found on osteoclasts and 
preosteoclast precursors. RANK-RANKL interactions lead 
to preosteoclast recruitment, fusion into multinucleated 
osteoclasts, osteoclast activation, and osteoclast survival. 
The pivotal role of this pathway in bone metabolism make 
it a prime target for the treatment of bone disease. The first 
commercially available drug to target the RANK-RANKL 
pathway is denosumab, a fully human monoclonal antibody 
that specifically binds and neutralizes RANKL, thereby 
inhibiting osteoclast function. The initial Phase I trials 
demonstrated that osteoclastic activity is almost completely 
eradicated while denosumab is in circulation.13 However, 
the effect is reversible, as indicated by a rise in markers of 
bone turnover when the drug is cleared.13
Initial trials with denosumab were in the treatment 
of women with primary osteoporosis. In the Phase III 
FREEDOM trial, 7868 postmenopausal women (aged 
60–90 years) with osteoporosis were randomly assigned 
to subcutaneous denosumab (60 mg every 6 months) or 
  placebo.14 After 3 years, denosumab improved bone mineral 
density compared with placebo. In addition, biochemical 
markers of bone turnover and fractures were significantly 
reduced in patients taking denosumab.14 When compared with 
bisphosphonates in the treatment of primary osteoporosis, 
denosumab has shown improvements in both bone mineral 
density and markers of bone loss.15
Denosumab has also been studied in bone loss associated 
with hormonal therapy in both breast and prostate cancer. 
In postmenopausal patients with hormone receptor-positive 
breast cancer, aromatase inhibitor use is associated with 
bone loss and increased fracture risk.16 Guidelines from the 
American Society of Clinical Oncology and the National 
Comprehensive Cancer Network recommend bone mineral 
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density testing with a dual-emission x-ray absorptiometry 
scan for postmenopausal women taking aromatase inhibitors 
and drug therapy for those with documented osteoporosis.17,18 
In a randomized, double-blind, placebo-controlled trial, 
252 women with hormone receptor-positive, early-stage 
breast cancer treated with adjuvant aromatase inhibitor 
therapy were randomly assigned to receive placebo or 
subcutaneous denosumab 60 mg every 6 months.19 At 
enrollment, all patients were required to have evidence of low 
bone mass (excluding osteoporosis). At 12 and 24 months, 
lumbar spine bone mineral density increased by 5.5% and 
7.6%, respectively, in the denosumab group compared with 
the placebo group (P = 0.0001). In the HALT (Hormone 
Ablation Bone Loss) trial, 1468 men receiving androgen 
deprivation therapy for nonmetastatic prostate cancer were 
randomly assigned to denosumab (60 mg subcutaneously 
every 6 months) or placebo.20 Eligibility included male 
gender, age $70 years or ,70 years with baseline low bone 
mineral density (T score at the lumbar spine, total hip, or 
femoral neck of less than −1.0). At 24 months, denosumab 
was associated with increased bone mineral density at all 
measured sites, including the total hip, femoral neck, distal 
third of the radius, and whole body (absolute difference 
versus placebo of 4.8%, 3.9%, 5.5%, and 4.0%, respectively, 
P , 0.001 for all comparisons). Because of the increased 
power of this larger study, a statistically significant decrease 
in new vertebral fractures at 36 months was also observed in 
the denosumab arm (1.5% versus 3.9% with placebo, relative 
risk, 0.38; 95% confidence interval, 0.19–0.78; P = 0.006). 
The promising outcomes in the initial trials with denosumab 
in treatment-related osteoporosis associated with breast and 
prostate cancer led to exploration of its use for the prevention 
of skeletal-related events in patients with solid tumors and 
bone metastasis, which is the focus of this review.
Dosing and side effects
Denosumab has US Food and Drug Administration (FDA) 
approval under two brand names. Under the brand name 
Prolia® (Amgen Inc, Thousand Oaks, CA), it is indicated for the 
treatment of primary osteoporosis in postmenopausal women 
at a dose of 60 mg subcutaneously every 6 months. This dose 
is also FDA-approved for the treatment of bone loss associated 
with aromatase inhibitor therapy in early-stage breast cancer 
and androgen deprivation therapy for nonmetastatic prostate 
cancer. Under the brand name Xgeva® (Amgen Inc), denosumab 
is FDA-approved for the prevention of skeletal-related events 
in patients with bone metastases from solid tumors at a dose 
of 120 mg subcutaneously every four weeks.
Denosumab absorption is rapid and sustained, with 
a   bioavailability of 62%, a steady-state mean serum 
concentration of 20.5 µg/mL, and an elimination half-life 
of 28 days.21 A decrease in bone resorption markers is 
observed within 24 hours after initial dose administration, 
and steady-state levels are achieved by 6 months following 
multiple doses at the 120 mg monthly schedule.13,21 The initial 
Phase I trial in healthy postmenopausal women demonstrated 
that a single denosumab dose of 3.0 mg/kg could suppress 
markers of bone turnover, including urinary collagen type 1 
crosslinked N-telopeptide (NTx), by up to 80% for a   duration 
of several months.13 In a Phase II trial of patients with bone 
metastases from solid tumors treated with denosumab, 
doses of 30–180 mg administered every 4 or 12 weeks were 
  compared with monthly intravenous bisphosphonate therapy 
in patients with elevated urinary NTx/creatinine levels 
despite intravenous bisphosphonate therapy.22 Patients treated 
with denosumab showed a significant decline in urinary 
NTx/creatinine ratio compared with patients who continued 
therapy with intravenous bisphosphonates, suggesting that 
denosumab may be superior to intravenous bisphosphonates 
at suppressing bone resorption.22 A second Phase II trial in 
patients with metastatic breast cancer treated with multiple 
doses and schedules of denosumab also confirmed a greater 
reduction in urinary NTx/creatinine levels in denosumab-
treated patients compared with intravenous bisphosphonate-
treated patients (74% versus 63%).23
Denosumab elimination is thought to occur through the 
immunoglobulin clearance pathway via the reticuloendothelial 
system, similar to that of other monoclonal antibodies 
and is thus thought to be independent of renal or hepatic 
function.24 The incidence of adverse events related to renal 
toxicity observed in the registration trials for preventing 
skeletal-  related events in patients with bone metastases was 
lower in the denosumab arm than in the zoledronic acid 
arm and similar to the rate seen in the observational arm 
of prior   bisphosphonate trials. The three larger Phase III 
registration trials comparing denosumab with zoledronic acid 
are discussed in further detail below. Dose reductions and 
renal monitoring are not required with denosumab therapy. 
However, there is a lack of safety data in patients with severe 
renal dysfunction because patients with creatinine clearance 
levels less than 30 mL/minute were excluded from the 
Phase III trials because the comparator, zoledronic acid, is 
contraindicated in this patient population. In the one small 
trial in which denosumab was administered as a single 
60 mg dose to 55 patients, including 17 patients with severe 
chronic renal disease (creatinine clearance #30 mL/minute) 
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or requiring hemodialysis, pharmacokinetics, and changes 
in biomarkers of bone resorption was unaffected by renal 
function. However, patients with severe chronic renal disease 
were at a greater risk of severe hypocalcemia with denosumab 
compared with patients with normal renal function.21 The risk 
of hypocalcemia at the dosing schedule used in the setting 
of bone metastasis (120 mg every 4 weeks) has not been 
adequately evaluated in patients with a creatinine clearance 
of less than 30 mL/minute or in those who are receiving 
dialysis. More frequent monitoring of serum calcium levels 
as well as ensuring adequate vitamin D levels prior to and 
upon initiation of denosumab therapy seems prudent in this 
population until additional safety studies are completed. The 
drug has also not been studied in the pediatric population.
In the setting of osteoporosis, the FREEDOM (Fracture 
Reduction Evaluation of Denosumab in Osteoporosis Every 
6 Months) trial is the largest single trial comparing denosumab 
with placebo for the prevention of fractures.14 In this study, 
there were no significant differences between the 3900 
subjects who received denosumab and those who received 
placebo with regard to the total incidence of adverse events, 
serious adverse events, or discontinuation of study treatment 
because of adverse events.14 In addition, there was no increase 
in the risk of cancer, overall rate of infection, cardiovascular 
disease, delayed fracture healing, or hypocalcemia, and 
there were no cases of osteonecrosis of the jaw. Neutralizing 
antibodies against denosumab have not been identified.
Because RANKL is expressed on subsets of T and B cells, 
there is a theoretical possibility that denosumab may be 
immunosuppressive. RANKL-deficient mice lack normal 
lymph node development and have inhibition of early T and 
B lymphocyte development.25 However, in clinical trials, 
a statistically significant or clinically meaningful effect on 
the immune system has not been observed. In one early trial, 
denosumab therapy had no significant effect on mean white 
blood cell counts, absolute lymphocyte counts, T and B cell 
counts, or immunoglobulins, and no meaningful difference 
was seen regarding incidence of infection.13 Phase II and III 
trials of denosumab for the treatment and prevention of 
osteoporosis suggested a slight increase in the rate of certain 
infectious complications, including cellulitis.14,26 However, 
the overall infection rate did not differ from placebo, and 
an association between denosumab and serious adverse 
infectious events has not been observed in any of the 
three large Phase III registration trials in cancer patients. 
Table 1 summarizes the adverse events observed in the three 
Phase III trials in patients with breast cancer, prostate cancer, 
and other solid tumors or multiple myeloma.
Disease-specific use
There have been three international Phase III randomized, 
double-blind, double-dummy, active controlled studies 
including over 5700 patients comparing denosumab with 
zoledronic acid for the prevention of skeletal-related events in 
patients with bone metastases. These three registration trials 
were of identical design and focused on the prevention of 
skeletal-related events in patients with breast cancer, prostate 
cancer, and other solid tumors or multiple myeloma, and led 
to FDA approval of denosumab for this indication.
Breast cancer
The first published Phase III trial enrolled 2046 patients 
with metastatic breast cancer and radiologic evidence of 
at least one bone metastasis.27 Patients with a creatinine 
clearance ,30 mL/minute were excluded because zoledronic 
acid is contraindicated in that patient population. Other 
exclusion criteria included prior bisphosphonate use for 
bone metastases and nonhealed dental/oral surgery. Patients 
were randomly assigned to receive either subcutaneous 
denosumab at 120 mg and intravenous placebo (n = 1026) 
or intravenous zoledronic acid 4 mg (with adjustment for 
creatinine clearance) and subcutaneous placebo (n = 1020) 
every 4 weeks. Supplementation with calcium $500 mg and 
vitamin D $ 400 IU daily was strongly encouraged. The 
primary endpoint was time to first skeletal-related event, 
with the study powered to detect noninferiority of denosumab 
versus zoledronic acid. Secondary endpoints included time 
to first on-study skeletal-related event (superiority test) 
and time to first and subsequent on-study skeletal-related 
event (multiple event analysis). The majority of patients in 
Table 1 Combined data for adverse events from three Phase iii 
registration trials in patients with breast cancer, prostate cancer, 
and other solid tumors or multiple myeloma38
Adverse event Denosumab 
(n = 2841)a
Zoledronic acid 
(n = 2836)a
Adverse events 2734 (96.2) 2745 (96.8)
Adverse events leading  
to study discontinuation
270 (9.5) 280 (9.9)
CTCAE Grade 3, 4, or  
5 adverse events
2000 (70.4) 2009 (70.8)
Serious adverse events 1599 (56.3) 1620 (57.1)
Adverse events of interest
Acute phase reactions  
(first 3 days)
246 (8.7) 572 (20.2)
Hypocalcemia 273 (9.6) 141 (5.0)
Osteonecrosis of the jaw 52 (1.8) 37 (1.3)
Note: aPatients who received at least one dose of active drug. 
Abbreviation: CTCAE, Common Terminology Criteria for Adverse Events.
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this study were postmenopausal, with hormone (estrogen/
progesterone) receptor-positive breast cancer. Denosumab 
delayed the time to first on-study skeletal-related event by 
18% compared with zoledronic acid (hazards ratio [HR] 
0.82; 95% confidence interval [CI] 0.71–0.95; P , 0.001 for 
noninferiority, P = 0.01 for superiority). Median time to first 
skeletal-related event was 26.4 months in the zoledronic acid 
group and had not yet been reached in the denosumab group at 
the time of the primary analysis. With an additional 4 months 
of blinded treatment, the median time to first skeletal-related 
event was reached in the denosumab arm at 32.4 months.28 
Denosumab also reduced the risk of subsequent skeletal-
related events by 23% (risk ratio 0.77; 95% CI 0.66–0.89, 
P = 0.001). Overall survival and disease progression were 
similar between the two groups. As in the Phase I and II trials, 
denosumab treatment resulted in greater suppression of bone 
turnover markers, including urinary NTx. At week 13, urinary 
NTx/creatinine levels decreased by 80% with denosumab and 
by 68% with zoledronic acid (P , 0.001).
The overall rates of serious adverse events and adverse 
events, including infectious complications, were similar 
between the two groups. Most of the observed adverse events 
were felt to be related to the patient’s concurrent chemother-
apy and/or advanced malignancy. However, several adverse 
events were different between the two arms, including the 
incidence of flu-like symptoms (acute-phase reactions, 
27.3% with zoledronic acid versus 10.4% with denosumab) 
and renal toxicity (8.5% with zoledronic acid versus 4.9% 
with denosumab). No patient treated with denosumab and 
10 patients (1%) treated with zoledronic acid experienced 
serious adverse events associated with acute-phase reactions 
during the first 3 days after treatment.29 These events included 
pyrexia (n = 7), bone pain (n = 2), and asthenia, back pain, 
chest pain, chills, headache, and malaise (n = 1 each). Nine 
of the 10 patients in the zoledronic acid group with serious 
acute-phase reactions required hospitalization or prolonga-
tion of hospitalization.29
Toothache, which was not associated with osteonecrosis 
of the jaw (5.6% denosumab versus 3.7% zoledronic 
acid) and hypocalcemia (5.5% denosumab versus 3.4% 
zoledronic acid) were more common in the denosumab 
group. None of the hypocalcemic events were fatal, and the 
majority required outpatient monitoring and additional oral 
or intravenous supplementation. Osteonecrosis of the jaw 
occurred infrequently in both groups and at rates that were 
not significantly different (2.0% in denosumab versus 1.4% 
in zoledronic acid, P = 0.39). The majority of patients who 
developed osteonecrosis of the jaw had known risk factors, 
including poor oral hygiene and/or prior dental extractions. 
As with zoledronic acid, the package insert for denosumab 
recommends that patients should consult a dentist and 
undergo preventive dentistry (ie, extraction of unsalvageable 
teeth) prior to initiating therapy with a bone-modifying agent 
to reduce the risk of osteonecrosis of the jaw.21
Patient-reported outcomes analyzed in the trial included 
pain using the Brief Pain Inventory and quality of life as 
assessed by the Functional Assessment of Cancer Therapy-
General (FACT-G) score.30 Patients were asked to complete 
the Brief Pain Inventory at baseline, day 8, and before each 
monthly visit through the end of study. In patients with 
scores of no/mild pain at baseline (n = 1042), median time 
to development of moderate/severe pain with denosumab 
was 295 days compared with 176 days in those treated with 
zoledronic acid (HR 0.78, 95% CI 0.67–0.92, P = 0.0024). 
The proportion of patients with no/mild pain at baseline who 
reported moderate/severe pain on-study was consistently 
lower for denosumab than for zoledronic acid through 
week 73. Time to pain improvement was similar between 
treatment arms (median 82 days for denosumab, median 
85 days for zoledronic acid; HR 1.02, 95% CI 0.91–1.15, 
P = 0.7245). Similarly, health-related quality of life was 
higher in the denosumab arm than in the zoledronic acid arm 
throughout the study, and a greater proportion of denosumab-
treated patients reported improvements in emotional and 
physical well-being.30
Based on the results of this trial and the FDA approval 
of denosumab for this indication, both the American Society 
of Clinical Oncology and National Comprehensive Cancer 
Network guidelines were updated to include therapy with 
denosumab at 120 mg subcutaneously every 4 weeks as a 
recommended regimen for preventing skeletal-related events 
in patients with bone metastases from breast cancer.18,31
Prostate cancer
The Phase III trial in prostate cancer randomized 1904 
patients with metastatic castrate-resistant prostate cancer 
to either denosumab or zoledronic acid treatment using an 
identical double-blind, double-dummy, active-controlled 
design.32 While skeletal lesions in prostate cancer are gener-
ally described as osteoblastic, osteoclast activity is known to 
be increased and to play an essential role. Patients with bone 
metastases from prostate cancer and high urinary NTx levels 
have an increased risk of skeletal-related events, time to a 
first skeletal-related event, disease progression, and death.33 
In the Phase III trial, eligible patients had histologically 
confirmed prostate cancer, evidence of at least one bone 
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metastases, and documented failure of at least one hormonal 
therapy. Exclusion criteria included current or previous 
treatment with bisphosphonates for bone metastases, planned 
radiation therapy or surgery to bone, life expectancy less 
than 6 months, current or previous osteonecrosis of the jaw, 
planned invasive dental procedures, and malignancy other 
than prostate cancer. Patients were strongly encouraged to 
take vitamin D and calcium supplementation. As in the breast 
cancer trial, patients were required to have a creatinine clear-
ance .30 mL/minute to be eligible for randomization to the 
zoledronic acid arm.
At the time of the primary analysis, patients had been 
on study for an average of 12.2 months in the denosumab 
group and 11.2 months in the zoledronic acid group.32 In 
the zoledronic acid arm, 22% of patients required dose 
adjustment for renal function and 15% of patients required 
doses to be held secondary to decreased renal function. 
In the denosumab arm, doses were not held or adjusted 
for renal function. Median time to first on-study skeletal-
related event was 20.7 months for patients on denosumab 
(95% CI 18.8–24.9) versus 17.1 months for those on zole-
dronic acid (95% CI 15.0–19.4), with an HR of 0.82 (95% 
CI 0.71–0.95, P = 0.002 for noninferiority and P = 0.008 
for superiority). This corresponds to a delay in time to first 
on-study skeletal-related event of 18% with denosumab 
compared with zoledronic acid, identical to the results from 
the similarly designed and powered trial in metastatic breast 
cancer. Denosumab also significantly delayed the time to first 
and subsequent on-study skeletal-related event (HR 0.82, 
95% CI 0.72–0.94, P = 0.004). Overall survival and disease 
progression were not significantly different between the 
treatment groups. At week 13, the decrease in urinary NTx/
creatinine was significantly greater in the denosumab group 
(median decrease of 84% in the denosumab group versus 69% 
in the zoledronic acid group, P , 0.0001). No neutralizing 
antibodies to denosumab were detected.
Overall, occurrence of adverse events and serious 
adverse events were similar between the groups. Hypocal-
cemia was more common in the denosumab group (13% 
in the denosumab group versus 6% in the zoledronic acid 
group, P , 0.0001). The majority of these cases were iso-
lated events and mild to moderate in severity. None of the 
episodes of hypocalcemia were fatal. The cumulative rate 
of osteonecrosis of the jaw between the two groups was 
not statistically significant, occurring in 1% (12 patients) 
in the zoledronic acid group versus 2% (22 patients) in the 
denosumab group. As in prior studies, the majority of these 
patients had a history of tooth extraction, a dental appliance, 
or poor oral hygiene. There was no difference in the rate of 
infection between the two groups. Adverse events associated 
with acute-phase reactions occurred in 8% of patients on 
denosumab and 18% of patients on zoledronic acid. Adverse 
events related to renal impairment were similar between the 
two groups, at 15% in the denosumab group and 16% in the 
zoledronic acid group. However, the zoledronic acid group 
required more frequent dose adjustment and dose-holding 
for renal dysfunction.
As in the Phase III study in breast cancer patients, the 
authors of this study concluded that denosumab was superior 
to zoledronic acid for the prevention of skeletal complica-
tions due to metastasis. Denosumab is recommended by the 
National Comprehensive Cancer Network as an option for 
the prevention of skeletal-related events in patients with 
metastatic prostate cancer.34
Solid tumors other than breast  
and prostate cancer
The third Phase III trial of denosumab in the setting of 
metastatic disease was carried out in 1776 patients with 
multiple myeloma or solid tumors other than breast or 
prostate cancer with at least one bone metastasis or osteolytic 
lesion.35 The study design was identical to that of the other 
two Phase III trials described previously. Approximately 
40% of enrolled patients had non-small cell lung cancer 
and 10% had multiple myeloma. At the time of primary 
analysis, only 20% of patients remained on study, with the 
majority of patients discontinuing therapy as a result of death 
(35%), withdrawal of consent (15%), or disease progression 
(13%). This trial had the shortest median time on study at 
approximately 7 months in both treatment groups.
The median time to first on-study skeletal-related event 
was 20.6 months for denosumab and 16.3 months for zole-
dronic acid. Denosumab was noninferior to zoledronic acid 
in delaying time to first on-study skeletal-related event (HR 
0.84, 95% CI 0.71–0.98, P = 0.0007), with superiority for 
denosumab nearing statistical significance at a P value of 
0.06. In this study, denosumab also failed to reduce time to 
first and subsequent skeletal-related events significantly with 
an HR of 0.90 for denosumab compared with zoledronic acid 
(95% CI 0.77–1.04, P = 0.14). Overall survival and disease 
progression were similar between the groups. The smaller 
number of patients randomized and shorter time on study 
yielded fewer skeletal-related events in this trial compared 
with the similarly designed breast and prostate trials, and 
thus may be the reason for the less dramatic improvements 
with denosumab seen in this study.
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As in prior studies, denosumab resulted in greater 
suppression of the urinary NTx/creatinine ratio (76% 
decrease in the denosumab groups versus 65% in those 
on zoledronic acid, P # 0.001). When stratified by tumor 
type, the HR for time to first on-study skeletal-related event 
for denosumab versus zoledronic acid was 0.84 (95% CI 
0.64–1.10, P = 0.20) for non-small cell lung cancer and 
0.76 for other solid tumors (95% CI 0.62–0.99, P = 0.04). 
However, the HR for the 180 patients treated with multiple 
myeloma was only 1.03 (95% CI 0.68–1.57, P = 0.89) and 
thus the FDA approval of denosumab is limited to patients 
with solid tumors and excludes treatment of patients with 
multiple myeloma. Currently, there is an ongoing large 
Phase III trial comparing denosumab with zoledronic acid 
therapy specifically in patients with multiple myeloma. 
Compared with zoledronic acid, the number needed-to-treat 
analysis showed that treatment of 9.9 patients with deno-
sumab would prevent one additional first skeletal-related 
event per patient-year.36 As in the Phase III trial in breast 
cancer patients, pain control was monitored at baseline, 
day 8, and before each monthly visit patients by the Brief 
Pain Inventory.37 Patients on denosumab experienced a 
delay in clinically significant pain worsening compared with 
patients on zoledronic acid (median 169 days in denosumab, 
143 days in zoledronic acid; HR 0.85, 95% CI 0.73–0.98, 
P = 0.02).
Patients in both groups experienced similar rates of 
overall adverse events.35 Hypocalcemia occurred more 
frequently in the denosumab group as compared with the 
zoledronic acid group (10.8% versus 5.8%), including grade 
3 or 4 hypocalcemia in 20 patients (2.3%) on denosumab and 
nine patients (1.0%) on zoledronic acid. As in prior stud-
ies, rates of osteonecrosis of the jaw were similar between 
the two groups (11 patients [1.3%] in the zoledronic acid 
group versus 10 patients [1.1%] in the denosumab group) 
and osteonecrosis of the jaw was seen primarily in patients 
with known risk   factors. Acute-phase reactions were more 
common in the zoledronic acid group (14.4% zoledronic acid 
versus 6.9% denosumab). Dose reduction was required in 
17.3%, and 8.9% of doses were held in patients on zoledronic 
acid due to renal   dysfunction. Despite these dose adjustments, 
renal dysfunction was more common in the zoledronic acid 
group (10.9% versus 8.3%).
A meta-analysis of the three registration Phase III trials 
in patients with bone metastasis was recently presented in 
abstract form and confirms the consistency of the data.38 The 
effects of denosumab versus zoledronic acid were evaluated 
with respect to time to first on-study skeletal-related event for 
noninferiority (primary endpoint) and superiority (secondary 
endpoint), and time to first and subsequent skeletal-related 
event (secondary endpoint). A total of 5723 patients were 
evaluated, 2861 in the zoledronic acid group and 2862 in the 
denosumab group. In this combined analysis, denosumab 
significantly prevented or delayed the time to first on-study 
skeletal-related event or hypercalcemia of malignancy, 
with a risk reduction of 17% (HR 0.83, 95% CI 0.76–0.90, 
P , 0.001 for both noninferiority and superiority). The 
median time to first on-study skeletal-related event was 
27.7 months with denosumab versus 19.4 months with 
zoledronic acid, resulting in a median delay of 8.2 months in 
favor of denosumab therapy. The effect of denosumab was 
consistent across all types of skeletal-related events (fracture, 
radiation, surgery, and spinal cord compression). These data 
are summarized in Table 2. In addition, combined analysis 
from the Phase III trials in patients with metastatic breast 
cancer and in patients with solid tumors other than breast or 
prostate cancer showed a significant decrease in hypercal-
cemia of malignancy in those treated with denosumab (HR 
0.63, 95% CI 0.41–0.98, P = 0.042).39 Disease progression 
and overall survival were similar between treatment groups, 
as was the incidence of all adverse events and serious adverse 
events. However, as with the individual trials, there was an 
increased incidence of hypocalcemia in the denosumab group 
(9.6% versus 5.0%) and acute-phase reactions (20.2% versus 
8.7%) in the zoledronic acid group (Table 1). Incidence of 
osteonecrosis of the jaw was infrequent and similar between 
the treatment groups, with a cumulative incidence of 1.3% 
Table 2 Hazard ratios for development of first skeletal-related 
event by type
Type of SRE Hazard ratio (95% CI)
Any SRE 0.83 (0.76–0.90),  
P , 0.001 in favor of denosumab
Pathological fracture 0.86 (0.76–0.96),  
P = 0.090 in favor of denosumab
Radiation to bone 0.77 (0.69–0.87),  
P # 0.001 in favor of denosumab
Spinal cord compression 0.89 (0.65–1.21),  
P = 0.45 in favor of denosumab
Surgery to bone 0.86 (0.61–1.21),  
P = 0.38 in favor of denosumab
Hypercalcemia of malignancya 0.63 (0.41–0.98),  
P = 0.042 in favor of denosumab
Notes: Combined data from three Phase iii registration trials in patients with breast 
cancer, prostate cancer, and other solid tumors or multiple myeloma.38,39 aincludes 
data from the two Phase iii registration trials in patients with breast cancer, and 
metastasis from solid tumors other than breast or prostate cancer and multiple 
myeloma. The metastatic prostate cancer trial was not included because of the low 
number of events. 
Abbreviations: CI, confidence interval; SRE, skeletal-related events.
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(37 events) in the zoledronic acid group compared with 1.8% 
(52 events) in the denosumab group. Further analysis of 
osteonecrosis of the jaw events suggested poor oral hygiene, 
dental extractions, and dental appliances accounted for the 
majority of cases, with up to 40% of the cases resolving 
with conservative therapies, including oral and/or   topical 
  antibiotics and surgical debridement after a median of 
8 months.40 Only 4% of patients required bone resection for 
refractory disease.
Recently, further safety data have been presented for 
denosumab use in patients with metastatic breast cancer, 
including patients on therapy for up to 5 years.41 In this 
analysis of patients from the open-label extension phase 
of the metastatic breast cancer registration trial, no new 
safety signals were observed in patients who switched from 
zoledronic acid to denosumab therapy or who remained 
on denosumab therapy for up to 5 years (median time on 
denosumab 19.1 months, range 0.1–59.8 months).
Future uses
The role of denosumab for the prevention of skeletal-related 
events in patients with bone metastasis from solid tumors 
has now been established in three large, well-designed, 
and definitive trials. Potential clinical questions include 
indications for and timing of transition from intravenous 
bisphosphonate to denosumab. Obvious indications 
for switching to denosumab include progressive renal 
insufficiency or intolerance to side effects associated 
with bisphosphonates. The Phase III STAND (Study of 
Transitioning from AleNdronate to Denosumab) trial 
looked at sequential use of oral bisphosphonates followed 
by denosumab in postmenopausal women with primary 
osteoporosis.42 Postmenopausal women at least 55 years 
of age with lumbar spine or total hip bone mineral density 
measurements corresponding to a T score of −2.0 to −4.0 
who had been receiving alendronate at 70 mg/week for at 
least 6 months were eligible. Subjects were randomized to 
denosumab 60 mg subcutaneously every 6 months versus 
continuing oral alendronate. All subjects were supplied 
with calcium and vitamin D supplements daily. The primary 
efficacy endpoint was the percentage change in total hip bone 
mineral density after 12 months of therapy. Bone mineral 
density at the total hip increased significantly more in patients 
transitioned to denosumab (1.90%, 95% CI 1.61%–2.18%) 
compared with patients continuing on alendronate (1.05%, 
95% CI 0.76%–1.34%, (P , 0.0001). Sequential use has also 
been explored in a Phase II trial in which 111 patients with 
solid tumors and bone metastasis previously treated with 
bisphosphonate were randomized to continue intravenous 
bisphosphonates versus switching to subcutaneous 
denosumab 180 mg subcutaneously every 4 or 12 weeks).22 
Urinary NTx was reduced to below 50 nmol/L by week 13 
(the primary endpoint) in 71% of patients on denosumab 
versus 29% of patients who continued on intravenous 
bisphosphonates (P , 0.001). The percentage of patients 
experiencing a first on-study skeletal-related event during 
the 25-week treatment period was 8% in the denosumab arm 
versus 17% in the intravenous bisphosphonate arm (odds 
ratio 0.31; 95% CI 0.08–1.18). These trials suggest a role 
for switching to denosumab in patients who are currently 
receiving oral or intravenous bisphosphonates and experience 
a skeletal-related event or who continue to have an elevated 
urinary NTx level despite bisphosphonate therapy. There 
are currently no data to support the combined use of a 
bisphosphonate plus denosumab to reduce osteoclast activity 
further. Because both agents are extremely potent osteoclast 
inhibitors, the risk of increased toxicity with combination 
therapy, especially with regard to osteonecrosis of the jaw 
development and hypocalcemia, would be concerning.
In addition to preventing skeletal-related events, a current 
area of active research for bone-modifying agents is in the 
prevention or delay of cancer progression. Recently, several 
trials in early-stage breast cancer patients suggest a role for 
bone-modifying agents in improving disease-free survival. The 
ABCSG-12 trial in premenopausal women with early-stage 
breast cancer is perhaps the most definitive of the recent trials, 
suggesting a role for bone-targeted therapy in the prevention 
of breast cancer recurrence.43 In this trial, patients treated with 
3 years of twice-yearly intravenous zoledronic acid had a 36% 
lower incidence of breast cancer recurrence compared with 
those treated with hormonal therapy alone. Unfortunately, the 
subsequent AZURE (Adjuvant Zoledronic Acid to Reduce 
Recurrence) trial, performed in a larger number of higher-
risk, early-stage breast cancer patients with stage II and III 
disease treated predominantly with chemotherapy alone versus 
chemotherapy plus higher intensity zoledronic acid, failed to 
show a similar improvement in breast cancer recurrence.44 
However, in subgroup analysis, there was an improvement 
in both disease-free and overall survival in older (.5 years 
postmenopausal) women treated with zoledronic acid.
There are data to suggest that RANKL may also be inte-
gral to the spread and propagation of cancer cells in bone.45 
The Phase III D-CARE trial is underway to assess the effect of 
denosumab on disease recurrence in patients with stage II and 
III high-risk, early-stage breast cancer.46 It is hypothesized that 
denosumab may have the potential to interrupt the “vicious 
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denosumab has no known renal toxicity, it may be the pre-
ferred choice in patients with baseline renal insufficiency 
receiving nephrotoxic chemotherapy, or in diseases more 
susceptible to renal dysfunction, such as renal cell cancer and 
prostate cancer. However, other toxicities, including osteone-
crosis of the jaw and hypocalcemia, are more commonly seen 
with denosumab than other less potent bisphosphonates (ie, 
pamidronate) and high-risk patients should be screened and 
monitored carefully for these toxicities. In addition, the added 
cost of denosumab as a novel and newly approved biologic 
agent, particularly with respect to the costs of generic bispho-
sphonates such as pamidronate, needs to be further evaluated 
in cost-effectiveness analyses. However, the improvements 
observed with denosumab compared with zoledronic acid in 
both pain control, quality of life, and convenience of admin-
istration for patients should not be underestimated. Both 
traditional cytotoxic and targeted chemotherapeutic agents 
remain essential, because poor control of metastatic disease is 
still the greatest risk factor for progression of bone disease and 
the development of skeletal-related events. However, the data 
presented here highlight the essential role bone-modifying 
agents such as denosumab play in maintaining the quality of 
life for patients with bone metastases.
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